Adamas Pharmaceuticals (ADMS) Hits New 12-Month Low at $6.22

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) reached a new 52-week low on Monday . The company traded as low as $6.22 and last traded at $6.40, with a volume of 11231 shares. The stock had previously closed at $6.44.

A number of equities research analysts have weighed in on the company. Needham & Company LLC downgraded Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 5th. Cowen downgraded Adamas Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $30.00 to $15.00 in a research report on Tuesday, March 5th. Mizuho downgraded Adamas Pharmaceuticals from a “neutral” rating to an “underperform” rating and cut their target price for the stock from $11.00 to $5.00 in a research report on Tuesday, March 5th. BidaskClub upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 25th. Finally, Zacks Investment Research downgraded Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 27th. One analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $23.88.

The stock has a market capitalization of $176.50 million, a price-to-earnings ratio of -1.35 and a beta of 1.43. The company has a debt-to-equity ratio of 1.31, a current ratio of 9.41 and a quick ratio of 9.20.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Monday, March 4th. The specialty pharmaceutical company reported ($1.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.30. The firm had revenue of $13.32 million during the quarter, compared to the consensus estimate of $13.30 million. Adamas Pharmaceuticals had a negative return on equity of 101.46% and a negative net margin of 384.77%. As a group, research analysts forecast that Adamas Pharmaceuticals Inc will post -4.14 EPS for the current fiscal year.

In other news, CEO Gregory T. Went sold 6,319 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $7.99, for a total transaction of $50,488.81. Following the completion of the sale, the chief executive officer now owns 176,291 shares in the company, valued at approximately $1,408,565.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 8,361 shares of company stock valued at $66,816 in the last quarter. Insiders own 24.60% of the company’s stock.

Large investors have recently made changes to their positions in the company. First Mercantile Trust Co. lifted its position in shares of Adamas Pharmaceuticals by 43.2% during the 4th quarter. First Mercantile Trust Co. now owns 5,765 shares of the specialty pharmaceutical company’s stock valued at $49,000 after acquiring an additional 1,740 shares during the last quarter. Advisor Group Inc. lifted its position in shares of Adamas Pharmaceuticals by 252.0% during the 4th quarter. Advisor Group Inc. now owns 6,300 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 4,510 shares during the last quarter. Pacer Advisors Inc. acquired a new stake in shares of Adamas Pharmaceuticals during the 3rd quarter valued at $104,000. Barclays PLC lifted its position in shares of Adamas Pharmaceuticals by 87.6% during the 4th quarter. Barclays PLC now owns 17,387 shares of the specialty pharmaceutical company’s stock valued at $148,000 after acquiring an additional 8,118 shares during the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Adamas Pharmaceuticals during the 4th quarter valued at $161,000. Institutional investors own 88.28% of the company’s stock.

WARNING: “Adamas Pharmaceuticals (ADMS) Hits New 12-Month Low at $6.22” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://sportsperspectives.com/2019/04/17/adamas-pharmaceuticals-adms-hits-new-12-month-low-at-6-22.html.

About Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Featured Article: Outstanding Shares, Buying and Selling Stocks

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.